TY - JOUR
T1 - Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma
AU - Thompson, Carrie A.
AU - Ghesquieres, Herve
AU - Maurer, Matthew J.
AU - Cerhan, James R.
AU - Biron, Pierre
AU - Ansell, Stephen M.
AU - Chassagne-Clément, Catherine
AU - Inwards, David J.
AU - Gargi, Thérèse
AU - Johnston, Patrick B.
AU - Nicolas-Virelizier, Emmanuelle
AU - Macon, William R.
AU - Peix, Marie
AU - Micallef, Ivana N.
AU - Sebban, Catherine
AU - Nowakowski, Grzegorz S.
AU - Porrata, Luis F.
AU - Weiner, George J.
AU - Witzig, Thomas E.
AU - Habermann, Thomas M.
AU - Link, Brian K.
N1 - Publisher Copyright:
© 2014 by American Society of Clinical Oncology.
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Methods Patients with newly diagnosed DLBCL and treated with anthracycline-based immunochemotherapy were identified from the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence and the Léon Bérard Cancer Center, Lyon, France. In those with relapse, details at relapse and outcomes were abstracted from records.Purpose: We examined the utility of post-therapy surveillance imaging in a large, prospectively enrolled cohort of patients with diffuse large B-cell lymphoma (DLBCL) from the United States and confirmed our results in an independent cohort of patients from France.Results: 680 individuals with DLBCL were identified from the MER, 552 (81%) of whom achieved remission after induction. 112 of the 552 patients (20%) suffered a relapse. The majority (64%) of relapses were identified before a scheduled follow-up visit. Surveillance imaging detected DLBCL relapse before clinical manifestations in nine out of 552 patients (1.6%) observed after therapy. In the Lyon cohort, imaging identified asymptomatic DLBCL relapse in four out of 222 patients (1.8%). There was no difference in survival after DLBCL relapse in patients detected at scheduled follow-up versus before scheduled follow-up in both the MER (P =.56) and Lyon cohorts (P =.25).Conclusion: The majority of DLBCL relapses are detected outside of planned follow-up, with no difference in outcome in patients with DLBCL detected at a scheduled visit compared with patients with relapse detected outside of planned follow-up. These data do not support the use of routine surveillance imaging for follow-up of DLBCL.
AB - Methods Patients with newly diagnosed DLBCL and treated with anthracycline-based immunochemotherapy were identified from the Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence and the Léon Bérard Cancer Center, Lyon, France. In those with relapse, details at relapse and outcomes were abstracted from records.Purpose: We examined the utility of post-therapy surveillance imaging in a large, prospectively enrolled cohort of patients with diffuse large B-cell lymphoma (DLBCL) from the United States and confirmed our results in an independent cohort of patients from France.Results: 680 individuals with DLBCL were identified from the MER, 552 (81%) of whom achieved remission after induction. 112 of the 552 patients (20%) suffered a relapse. The majority (64%) of relapses were identified before a scheduled follow-up visit. Surveillance imaging detected DLBCL relapse before clinical manifestations in nine out of 552 patients (1.6%) observed after therapy. In the Lyon cohort, imaging identified asymptomatic DLBCL relapse in four out of 222 patients (1.8%). There was no difference in survival after DLBCL relapse in patients detected at scheduled follow-up versus before scheduled follow-up in both the MER (P =.56) and Lyon cohorts (P =.25).Conclusion: The majority of DLBCL relapses are detected outside of planned follow-up, with no difference in outcome in patients with DLBCL detected at a scheduled visit compared with patients with relapse detected outside of planned follow-up. These data do not support the use of routine surveillance imaging for follow-up of DLBCL.
UR - http://www.scopus.com/inward/record.url?scp=84911476792&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84911476792&partnerID=8YFLogxK
U2 - 10.1200/JCO.2014.55.7561
DO - 10.1200/JCO.2014.55.7561
M3 - Article
C2 - 25267745
AN - SCOPUS:84911476792
SN - 0732-183X
VL - 32
SP - 3506
EP - 3512
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 31
ER -